Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 12, 2020 - Issue
Submit an article Journal homepage
130
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma

Eddie J Gibson1 Wickenstones Ltd, Abingdon, UKView further author information
,
Najida Begum1 Wickenstones Ltd, Abingdon, UKView further author information
,
Ian Koblbauer1 Wickenstones Ltd, Abingdon, UKView further author information
,
George Dranitsaris2 Augmentium Pharma Consulting Inc., Toronto, ON, CanadaView further author information
,
Danny Liew3 School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, AustraliaView further author information
,
Phil McEwan4 Health Economics and Outcomes Research Ltd, Cardiff, UKORCID Iconhttps://orcid.org/0000-0001-7488-9058View further author information
ORCID Icon,
Yong Yuan5 Bristol-Myers Squibb, Lawrenceville, NJ, USAView further author information
,
Ariadna Juarez-Garcia6 Bristol-Myers Squibb, Uxbridge, UKView further author information
,
David Tyas6 Bristol-Myers Squibb, Uxbridge, UKView further author information
&
Clive Pritchard1 Wickenstones Ltd, Abingdon, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7656-0862View further author information
ORCID Icon show all
Pages 241-252 | Published online: 06 May 2020

References

  • NICE. National Institute for Health and Care Excellence: proposals for increasing capacity within NICE’s technology appraisal [Internet]; 2017. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/technology-appraisals/increasing-ta-capacity-consultation.pdf. Accessed April 7, 2020.
  • Miller JD, Foley KA, Russell MW. Current challenges in health economic modeling of cancer therapies: a research inquiry. Am Health Drug Benefits. 2014;7:153–162.
  • Jönsson B, Wilking N. Cancer vaccines and immunotherapeutics: challenges for pricing, reimbursement and market access. Hum Vaccines Immunother. 2012;8:1360–1363. doi:10.4161/hv.21921
  • Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23:1920–1928. doi:10.1158/1078-0432.CCR-16-1741
  • Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420. doi:10.1158/1078-0432.CCR-09-1624
  • Anagnostou V, Yarchoan M, Hansen AR, et al. Immuno-oncology trial endpoints: capturing clinically meaningful activity. Clin Cancer Res. 2017;23:951–959. doi:10.1158/1078-0432.CCR-16-3065
  • Gibson E, Koblbauer I, Begum N, et al. Modelling the survival outcomes of immuno-oncology drugs in economic evaluations: a systematic approach to data analysis and extrapolation. Pharmacoeconomics. 2017:1–14.
  • Gibson EJ, Begum N, Koblhauer I, et al. Modeling the economic outcomes of immuno- oncology drugs: alternative model frameworks to capture clinical outcomes. Clin Outcomes Res. 2018;10:139–154.
  • Chen -T-T. Statistical issues and challenges in immuno-oncology. J Immunother Cancer. 2013;1:18.
  • Gibson EJ, Begum N, Koblbauer I, et al. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. J Med Econ. 2019;22.
  • Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase ii and phase iii trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1–7.
  • NICE. Guide to the Methods of Technology Appraisal. Vol. 2013. London: National Institute for Health and Care Excellence; 2013.
  • Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–1356.
  • Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12.
  • Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob -J-J, Rutkowski P, Cowey CL. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, Phase 3 trial. Lancet Oncol. 2018;19:P1480–1491. doi:10.1016/S1470-2045(18)30700-9
  • Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. doi:10.1056/NEJMoa1504030
  • Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for cured patients in cost-effectiveness analysis. Value Heal. 2017;20.
  • BMS. Nivolumab combined with ipilimumab or alone outperforms ipilimumab at 5 years in advanced melanoma [Internet]. ESMO2019; Nivolumab Combined with Ipilimumab or Alone Outperforms Ipilimumab at 5 Years in Advanced Melanoma. Accessed November 7, 2019.
  • Office for National Statistics. National life tables, United Kingdom (2015-17 life tables) [Internet]; 2018. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables. Accessed December 10, 2018].
  • Beusterien KM, Szabo SM, Kotapati S, et al. Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer. 2009;101:387–389.
  • Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480–1492. doi:10.1016/S1470-2045(18)30700-9
  • Ouwens MJNM, Mukhopadhyay P, Zhang Y, Huang M, Latimer N, Briggs A. Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations. Pharmacoeconomics. 2019;37:1129–1138.
  • NICE. Final Appraisal Determination Nivolumab in Combination with Ipilimumab for Treating Advanced Melanoma. 2016:1–24
  • Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Heal Serv Res Policy. 2004;9:110–118.
  • Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15:1295–1310. doi:10.1002/hec.1148

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.